Systemic interleukin 12 therapy has potent antitumor effects, but clinical delivery of this potent cytokine has been complicated by systemic toxicity. A novel strategy to deliver IL-12 to the tumor microenvironment appears promising in a first-in-human study, appearing to stimulate tumor specific adaptive immune responses with minimal systemic toxicity.
https://ift.tt/2ACcJT5
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου
Σημείωση: Μόνο ένα μέλος αυτού του ιστολογίου μπορεί να αναρτήσει σχόλιο.